Abstract:Background: Many human diseases are associated with dysregulation of HDACs. HDAC6 exhibits deacetylase activity not only to histone protein but also to non-histone proteins such as α- tubulin, HSP90, cortactin, and peroxiredoxin. These unique functions of HDAC6 have gained significant attention in the medicinal chemistry community in recent years. Thus a great deal of effort has devoted to developing selective HDAC6 inhibitors for therapy with the hope to minimize the side effects caused by pan-HDAC inhibition. Objective: The review intends to analyze the structural feature of the scaffolds, to provide useful information for those who are interested in this field, as well as to spark the future design of the new inhibitors. Methods: The primary tool used for patent searching is SciFinder. All patents are retrieved from the following websites: the World Intellectual Property Organization (WIPO®), the United States Patent Trademark Office (USPTO®), Espacenet®, and Google Patents. The years of patents covered in this review are between 2016 and 2019. Results: Thirty-six patents from seventeen companies/academic institutes were classified into three categories based on the structure of ZBG: hydroxamic acid, 1,3,4-oxadiazole, and 1,2,4-oxadiazole. ZBG connects to the cap group through a linker. The cap group can tolerate different functional groups, including amide, urea, sulfonamide, sulfamide, etc. The cap group appears to modulate the selectivity of HDAC6 over other HDAC subtypes. Conclusion: Selectively targeting HDAC6 over other subtypes represents two fold advantages: it maximizes the pharmacological effects and minimizes the side effects seen in pan-HDAC inhibitors. Many small molecule selective HDAC6 inhibitors have advanced to clinical studies in recent years. We anticipate the approval of selective HDAC6 inhibitors as therapeutic agents in the near future.

Histone deacetylase 6 structure and molecular basis of catalysis and inhibition

[Histone Deacetylase 6: Structure, Functions and Development of Selective Inhibitors].

Structure, Functions and Selective Inhibitors of HDAC6

Recent Development of Novel HDAC6 Isoform-Selective Inhibitors.

A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity

Hdac6: Physiological Function And Its Selective Inhibitors For Cancer Treatment

Crystal structure of histone deacetylase 6 complexed with (R)-lipoic acid, an essential cofactor in central carbon metabolism

Histone deacetylase 6 in cancer

Histone deacetylase 6's function in viral infection, innate immunity, and disease: latest advances

Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019)

Inhibition And Mechanism Of Hdac8 Revisited

Proteomic Identification and Functional Characterization of MYH9, Hsc70, and DNAJA1 As Novel Substrates of HDAC6 Deacetylase Activity

The Cytoplasmic Deacetylase HDAC6 is Required for Efficient Oncogenic Tumorigenesis

Discovery of a fluorescent probe with HDAC6 selective inhibition.

[Histone Deacetylase 6: the Key Regulator of Misfolded Proteins].

Cellular Defence or Viral Assist: the Dilemma of HDAC6

Design, synthesis, and biological evaluation of HDAC6 inhibitors targeting L1 loop and serine 531 residue

Development of a histone deacetylase 6 inhibitor and its biological effects

Curriculum vitae of HDAC6 in solid tumors

Cellular defence or viral assist: the dilemma of HDAC6.

Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases